Table 5 Most commonly occurring treatment emergent adverse eventsa (safety population; N = 140).

From: In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

  

Age

Frailty status

TEAEs, n (%)

Overall (N = 140)

<75 years (n = 81)

≥75 years (n = 59)

Non-frail (n = 54)

Frail (n = 86)

Diarrhea

71 (50.7)

40 (49.4)

31 (52.5)

27 (50.0)

44 (51.2)

 Grade 1–2

58 (41.4)

34 (42.0)

24 (40.7)

20 (37.0)

38 (44.2)

 Grade ≥3

13 (9.3)

6 (7.4)

7 (11.9)

7 (13.0)

6 (7.0)

PN

39 (27.9)

24 (29.6)

15 (25.4)

12 (22.2)

27 (31.4)

 Grade 1–2

36 (25.7)

22 (27.2)

14 (23.7)

10 (18.5)

26 (30.2)

 Grade ≥3

3 (2.1)

2 (2.5)

1 (1.7)

2 (3.7)

1 (1.2)

Fatigue

47 (33.6)

29 (35.8)

18 (30.5)

15 (27.8)

32 (37.2)

 Grade 1─2

42 (30.0)

27 (33.3)

15 (25.4)

12 (22.2)

30 (34.9)

 Grade ≥3

5 (3.6)

2 (2.5)

3 (5.1)

3 (5.6)

2 (2.3)

Nausea

35 (25.0)

23 (28.4)

12 (20.3)

11 (20.4)

24 (27.9)

 Grade 1–2

31 (22.1)

22 (27.2)

9 (15.3)

11 (20.4)

20 (23.3)

 Grade ≥3

4 (2.9)

1 (1.2)

3 (5.1)

0

4 (4.7)

Peripheral edema

36 (25.7)

23 (28.4)

13 (22.0)

14 (25.9)

22 (25.6)

 Grade 1–2

35 (25.0)

23 (28.4)

12 (20.3)

14 (25.9)

21 (24.4)

 Grade ≥3

1 (0.7)

0

1 (1.7)

0

1 (1.2)

Arthralgia

31 (22.1)

21 (25.9)

10 (16.9)

11 (20.4)

20 (23.3)

 Grade 1–2

28 (20.0)

19 (23.5)

9 (15.3)

10 (18.5)

18 (20.9)

 Grade ≥3

3 (2.1)

2 (2.5)

1 (1.7)

1 (1.9)

2 (2.3)

Back pain

26 (18.6)

17 (21.0)

9 (15.3)

8 (14.8)

18 (20.9)

 Grade 1–2

23 (16.4)

15 (18.5)

8 (13.6)

8 (14.8)

15 (17.4)

 Grade ≥3

3 (2.1)

2 (2.5)

1 (1.7)

0

3 (3.5)

Constipation

24 (17.1)

12 (14.8)

12 (20.3)

7 (13.0)

17 (19.8)

 Grade 1–2

24 (17.1)

12 (14.8)

12 (20.3)

7 (13.0)

17 (19.8)

 Grade ≥3

0

0

0

0

0

Hypokalemia

25 (17.9)

12 (14.8)b

13 (22.0)

3 (5.6)

22 (25.6)b

 Grade 1–2

19 (13.6)

10 (12.3)

9 (15.3)

2 (3.7)

17 (19.8)

 Grade ≥3

6 (4.3)

2 (2.5)

4 (6.8)

1 (1.9)

5 (5.8)

Rash

24 (17.1)

14 (17.3)

10 (16.9)

7 (13.0)

17 (19.8)

 Grade 1–2

20 (14.3)

11 (13.6)

9 (15.3)

6 (11.1)

14 (16.3)

 Grade ≥3

4 (2.9)

3 (3.7)

1 (1.7)

1 (1.9)

3 (3.5)

Pneumonia

18 (12.9)

10 (12.3)

8 (13.6)

6 (11.1)

12 (14.0)

 Grade 1–2

9 (6.4)

7 (8.6)

2 (3.4)

5 (9.3)

4 (4.7)

 Grade ≥3

9 (6.4)

3 (3.7)

6 (10.2)

1 (1.9)

8 (9.3)

  1. PN peripheral neuropathy, TEAE treatment emergent adverse event.
  2. aIn >15% of patients at any grade or >5% at grade ≥3. None of the TEAEs in this table were grade 4, except where indicated.
  3. b1 patient aged <75 years, deemed frail, had grade 4 hypokalemia.
Back to article page